Progressive Weight Loss-Induced Remission of Insulin Resistance/Hyperinsulinemia and Improvements in Cardiovascular Risk Factors
Abstract
Background: Hyperinsulinemia (HI) is a common endocrine metabolic disorder in obesity and is closely associated with cardiovascular disease.
Aim: This study aims to investigate the effects of progressive weight reduction on HI and cardiovascular risk factors.
Methods: We enrolled 68 patients with overweight or obesity. Body composition assessments, clinical indicator sampling and a 75g-oral glucose tolerance test were conducted at baseline and after 12-month weight loss to assess HI and insulin sensitivity. And the people were divided into four groups based on the percent of weight loss (30%) to study the remission of HI and changes in body composition and cardiovascular risk factors.
Results: A total of 66 participants were studied at the end. Progressive weight loss significantly reduced plasma glucose and insulin (PP for trend P for trend P for trend <0.001), which reaches 100% when weight loss exceeds 30%. After adjusting for factors such as age, gender, and medication usage, remission of HI was still associated with progressive weight loss.
Conclusion: With progressive weight loss, people with overweight or obesity experienced further improvements in glycemic outcomes, body compositions, HI and insulin resistance.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 68 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.